Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Increased to $430.00 by Analysts at HC Wainwright

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) had its target price increased by analysts at HC Wainwright from $400.00 to $430.00 in a report issued on Monday, The Fly reports. HC Wainwright’s price target would indicate a potential upside of 222.27% from the stock’s previous close.

A number of other brokerages also recently issued reports on ALNY. StockNews.com started coverage on Alnylam Pharmaceuticals in a report on Thursday, March 31st. They issued a “hold” rating for the company. Oppenheimer reissued an “outperform” rating and issued a $205.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 6th. Morgan Stanley downgraded Alnylam Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $210.00 to $178.00 in a research note on Monday, April 25th. Stifel Nicolaus reaffirmed a “buy” rating and set a $215.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, March 24th. Finally, SVB Leerink reduced their target price on Alnylam Pharmaceuticals from $109.00 to $103.00 and set a “market perform” rating for the company in a research note on Friday, February 11th. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $219.76.

Shares of NASDAQ ALNY opened at $133.43 on Monday. The business’s 50 day moving average price is $160.27 and its 200 day moving average price is $166.05. The firm has a market cap of $16.11 billion, a P/E ratio of -17.81 and a beta of 0.85. Alnylam Pharmaceuticals has a 52 week low of $125.00 and a 52 week high of $212.00. The company has a quick ratio of 3.91, a current ratio of 4.04 and a debt-to-equity ratio of 1.15.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last issued its earnings results on Thursday, April 28th. The biopharmaceutical company reported ($2.00) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.84) by ($0.16). Alnylam Pharmaceuticals had a negative net margin of 101.46% and a negative return on equity of 121.90%. The firm had revenue of $186.90 million during the quarter, compared to analysts’ expectations of $242.82 million. During the same quarter in the prior year, the company earned ($1.71) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 37.6% on a year-over-year basis. As a group, research analysts expect that Alnylam Pharmaceuticals will post -6.94 earnings per share for the current year.

In other news, Director Steven M. Paul sold 15,000 shares of the firm’s stock in a transaction dated Friday, April 1st. The stock was sold at an average price of $170.69, for a total transaction of $2,560,350.00. Following the sale, the director now owns 1,000 shares of the company’s stock, valued at approximately $170,690. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.40% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in the business. Baillie Gifford & Co. grew its stake in shares of Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Baillie Gifford & Co. now owns 10,616,751 shares of the biopharmaceutical company’s stock valued at $1,800,388,000 after purchasing an additional 200,967 shares during the last quarter. BlackRock Inc. grew its stake in shares of Alnylam Pharmaceuticals by 2.6% in the 3rd quarter. BlackRock Inc. now owns 8,920,972 shares of the biopharmaceutical company’s stock valued at $1,684,369,000 after purchasing an additional 224,569 shares during the last quarter. Dodge & Cox grew its stake in shares of Alnylam Pharmaceuticals by 1.1% in the 4th quarter. Dodge & Cox now owns 5,431,068 shares of the biopharmaceutical company’s stock valued at $921,001,000 after purchasing an additional 58,968 shares during the last quarter. State Street Corp grew its stake in shares of Alnylam Pharmaceuticals by 1.8% in the 4th quarter. State Street Corp now owns 2,850,389 shares of the biopharmaceutical company’s stock valued at $483,369,000 after purchasing an additional 49,564 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 1,505,291 shares of the biopharmaceutical company’s stock valued at $254,889,000 after purchasing an additional 51,272 shares during the last quarter. Institutional investors own 92.39% of the company’s stock.

Alnylam Pharmaceuticals Company Profile (Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Recommended Stories